NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Get Started
$61.50 +0.77 (+1.27 %)
(As of 04/19/2019 04:00 PM ET)
Previous Close$61.50
Today's Range$60.1050 - $62.10
52-Week Range$56.58 - $91.35
Volume1.79 million shs
Average Volume1.85 million shs
Market Capitalization$9.19 billion
P/E Ratio14.89
Dividend YieldN/A
Beta0.88
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York.

Receive HSIC News and Ratings via Email

Sign-up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical & hospital equipment
Sub-IndustryHealth Care Distributors
SectorMedical
Current SymbolNASDAQ:HSIC
Previous Symbol
CUSIP80640710
CIK1000228
Webwww.henryschein.com
Phone631-843-5500

Debt

Debt-to-Equity Ratio0.28
Current Ratio1.30
Quick Ratio0.68

Price-To-Earnings

Trailing P/E Ratio14.89
Forward P/E Ratio17.93
P/E Growth2.3

Sales & Book Value

Annual Sales$13.20 billion
Price / Sales0.70
Cash Flow$5.4960 per share
Price / Cash Flow11.19
Book Value$23.23 per share
Price / Book2.65

Profitability

EPS (Most Recent Fiscal Year)$4.13
Net Income$535.88 million
Net Margins4.06%
Return on Equity19.86%
Return on Assets7.79%

Miscellaneous

Employees18,000
Outstanding Shares149,471,000
Market Cap$9.19 billion
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Henry Schein (NASDAQ:HSIC) Frequently Asked Questions

What is Henry Schein's stock symbol?

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

When did Henry Schein's stock split? How did Henry Schein's stock split work?

Henry Schein shares split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were payable to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein declared that its Board of Directors has authorized a share buyback program on Thursday, December 13th 2018, which allows the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 3.1% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its shares are undervalued.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) posted its quarterly earnings results on Wednesday, February, 20th. The company reported $1.12 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.01. The company had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.46 billion. Henry Schein had a return on equity of 19.86% and a net margin of 4.06%. The company's quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.97 earnings per share. View Henry Schein's Earnings History.

When is Henry Schein's next earnings date?

Henry Schein is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Henry Schein.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein issued an update on its FY19 earnings guidance on Wednesday, February, 20th. The company provided earnings per share guidance of $3.38-3.46 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.75. Henry Schein also updated its FY 2019 guidance to $3.38-3.46 EPS.

What price target have analysts set for HSIC?

17 equities research analysts have issued 1-year price targets for Henry Schein's shares. Their predictions range from $62.00 to $102.00. On average, they expect Henry Schein's stock price to reach $78.1327 in the next year. This suggests a possible upside of 27.0% from the stock's current price. View Analyst Price Targets for Henry Schein.

What is the consensus analysts' recommendation for Henry Schein?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 4 sell ratings, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

What are Wall Street analysts saying about Henry Schein stock?

Here are some recent quotes from research analysts about Henry Schein stock:
  • 1. According to Zacks Investment Research, "Henry Schein exited the fourth quarter of 2018 on a mixed note. We are disappointed with the year-over-year deterioration in gross and operating margin due to higher expenses. Pricing pressure, tough competition and adverse currency movements are other concerns. Nonetheless, Henry Schein saw solid performance by the global Medical and Technology and Value-added Services businesses. The company's strong share gain in the North American market raises optimism. Moreover, management seems to be upbeat about the creation of the Henry Schein One dental technology business and the completion of the spin-off of its animal health business into Covetrus. We are looking forward to Henry Schein’s new agreement to buy a dental practice management solutions company, Kopfwerk. In the past six months, Henry Schein has underperformed the S&P market." (2/26/2019)
  • 2. Barrington Research analysts commented, "We are currently modeling $4.10. It is important to note that management’s adjusted EPS guidance does not include any impact from the upcoming animal health spin-off and merger, which is expected to occur around year end. In addition, the guidance does not factor in any future M&A activity." (11/8/2018)

Has Henry Schein been receiving favorable news coverage?

Press coverage about HSIC stock has been trending somewhat positive on Saturday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Henry Schein earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Henry Schein's key competitors?

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Alexion Pharmaceuticals (ALXN), Celgene (CELG), Citigroup (C), CVS Health (CVS), NVIDIA (NVDA), Honeywell International (HON), Activision Blizzard (ATVI), Micron Technology (MU) and United Parcel Service (UPS).

Who are Henry Schein's key executives?

Henry Schein's management team includes the folowing people:
  • Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 69)
  • Mr. James P. Breslawski, Vice Chairman & Pres (Age 65)
  • Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 62)
  • Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Director (Age 66)
  • Mr. Ronald South, Chief Accounting Officer & VP of Corp. Fin.

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by many different of retail and institutional investors. Top institutional investors include BTIM Corp. (0.43%), Fenimore Asset Management Inc. (0.36%), Riverbridge Partners LLC (0.25%), PGGM Investments (0.21%), DNB Asset Management AS (0.13%) and Bell Asset Management Ltd (0.09%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Gerald A Benjamin, Mark E Mlotek, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

Which major investors are selling Henry Schein stock?

HSIC stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, State of Alaska Department of Revenue, Steinberg Global Asset Management, Fenimore Asset Management Inc., Riverbridge Partners LLC, Aurora Investment Counsel, Neville Rodie & Shaw Inc. and Gateway Investment Advisers LLC. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, Mark E Mlotek, Michael S Ettinger, Paul Brons, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Insider Buying and Selling for Henry Schein.

Which major investors are buying Henry Schein stock?

HSIC stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, BTIM Corp., PGGM Investments, Bell Asset Management Ltd, Tibra Equities Europe Ltd, Bell Rock Capital LLC, Palisade Asset Management LLC and NuWave Investment Management LLC. View Insider Buying and Selling for Henry Schein.

How do I buy shares of Henry Schein?

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Henry Schein's stock price today?

One share of HSIC stock can currently be purchased for approximately $61.50.

How big of a company is Henry Schein?

Henry Schein has a market capitalization of $9.19 billion and generates $13.20 billion in revenue each year. The company earns $535.88 million in net income (profit) each year or $4.13 on an earnings per share basis. Henry Schein employs 18,000 workers across the globe.

What is Henry Schein's official website?

The official website for Henry Schein is http://www.henryschein.com.

How can I contact Henry Schein?

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]


MarketBeat Community Rating for Henry Schein (NASDAQ HSIC)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  485 (Vote Underperform)
Total Votes:  760
MarketBeat's community ratings are surveys of what our community members think about Henry Schein and other stocks. Vote "Outperform" if you believe HSIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/20/2019 by MarketBeat.com Staff

Featured Article: Cash Flow Analysis in Stock Selection
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel